ERBB2 and breast carcinoma: The patient cohort consisted of 35 patients with HER2+++ expression on breast cancer cells defined by immunohistopathology and confirmation for HER2 gene amplification by FISH, 37 patients with intermediate/low HER2++/+ expression and no detection of HER2 gene amplification, and 43 HER2neg patients.